RCS - Destiny Pharma PLC - XF-73 prevents bacterial invasion of bloodstream

Destiny PharmaAnnouncement

05/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240805:nRSE0740Za&default-theme=true

RNS Number : 0740Z  Destiny Pharma PLC  05 August 2024

Destiny Pharma plc
("Destiny Pharma" or "the Company")

 

XF-73 treatment of MRSA burn wound infection prevents bacterial invasion of
the bloodstream

 

Data to be presented at the Infection Prevention Society conference

 

Brighton, United Kingdom - 5 August 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, today announced that new data on its lead drug, Exeporfinium
chloride(XF-73)*, has been accepted for presentation at the Infection
Prevention Society conference on the 23-25 September 2024 in Birmingham, UK.

 

The title of the presentation is, 'Inhibition of MRSA Infection by
Exeporfinium Chloride (XF-73) in an In Vivo Burn Wound Model.'

 

The data was generated from a study in which XF-73 was applied directly onto a
methicillin resistant Staphylococcus aureus (MRSA) infected burn wound with
subsequent monitoring of the spread of the MRSA into the bloodstream. When
bacteria such as MRSA enter the bloodstream it can cause a life-threatening
infection condition called sepsis which has a high mortality rate. The study
also included a control placebo treatment arm.

 

The headline results which will be presented at the Infection Prevention
Society conference include:

 

·    Following a single topical application of 25, 50 or 100 µg of XF-73,
MRSA infection within the burn wound tissue was significantly reduced by up to
99.99% compared to the placebo treatment, (p<0.05)

 

·    The appearance of MRSA within the bloodstream (i.e. sepsis) was
measured by monitoring the number of MRSA bacteria within the spleen and
results from the three XF-73 dosed groups (each n=8) showed a significant
99.9% reduction of MRSA reaching the bloodstream, (p<0.05)

 

·    In one of the XF-73 treatment groups, (50 µg), it was observed that
no MRSA had reached the bloodstream resulting in the complete prevention of
sepsis

 

Globally, it is estimated that there are approximately 9 million burn cases
per year(1). Burn injuries contribute to >250,000 fatalities(2) with
infections identified as the cause of 61% of post-burn deaths(3). Recent
reports show the incidence of sepsis in burn patients ranges from 8% to 42%
with related mortality from 28-65%(4). Staphylococcus aureus, (including
MRSA), is a common cause of post-burn infection, with reports that patients
with burns had a prevalence of S. aureus of 57.8%(5).

 

Dr Bill Love, Chief Scientific Officer Destiny Pharma, said: "These results
from an in vivo burn wound infection model provide clear evidence that XF-73
can significantly reduce the risk, or even eliminate MRSA from reaching the
bloodstream and causing sepsis. It is seen as a significant result for the
continued development of our XF-73 dermal product."

 

* XF-73, is a di-cationic porphyrin derivative with known rapid and potent
bactericidal properties (MICs 0.25-4mg/L for all Gram positive bacteria tested
to date) with a low propensity for engendering bacterial resistance. XF-73 has
recently completed Phase 2 clinical study as an intranasal gel for
decolonization of S. aureus, (including MRSA), to prevent post-surgical
infections.

 

References:

1.  Greenhalgh DG. Management of Burns. N Engl J Med. 2019 Jun
13;380(24):2349-2359. doi: 10.1056/NEJMra1807442. PMID: 31189038.

2.    Moeini A, Pedram P, Makvandi P, Malinconico M, Gomez d'Ayala G. Wound
healing and antimicrobial effect of active secondary metabolites in
chitosan-based wound dressings: A review. Carbohydr Polym. 2020 Apr
1;233:115839. doi: 10.1016/j.carbpol.2020.115839. Epub 2020 Jan 13. PMID:
32059889.

3.    Gomez R, Murray CK, Hospenthal DR, Cancio LC, Renz EM, Holcomb JB,
Wade CE, Wolf SE. Causes of mortality by autopsy findings of combat casualties
and civilian patients admitted to a burn unit. J Am Coll Surg. 2009
Mar;208(3):348-54. doi: 10.1016/j.jamcollsurg.2008.11.012. Epub 2009 Jan 21.
PMID: 19317995.

4.    Cabral L, Afreixo V, Santos F, Almeida L, Paiva JA. Procalcitonin for
the early diagnosis of sepsis in burn patients: A retrospective study. Burns.
2017 Nov;43(7):1427-1434. doi: 10.1016/j.burns.2017.03.026. Epub 2017 Apr 25.
PMID: 28454850.

5.    Alebachew T, Yismaw G, Derabe A, Sisay Z. Staphylococcus aureus burn
wound infection among patients attending yekatit 12 hospital burn unit, addis
ababa, ethiopia. Ethiop J Health Sci. 2012 Nov;22(3):209-13. PMID: 23209356;
PMCID: PMC3511900.

 

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGCGDIBXGDGSS